We are live on ! Find out more
NRD

Nebula Research & Development Portfolio holdings

AUM $1.17B
1-Year Est. Return 15.19%
This Fund
S&P 500
This Quarter Est. Return
+7.19%
1 Year Est. Return
+15.19%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$836M
AUM Growth
+$219M
Cap. Flow
+$188M
Cap. Flow %
22.5%
Top 10 Hldgs %
4.49%
Holding
1,220
New
441
Increased
247
Reduced
213
Closed
319

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$4.41M
2
AAP icon
Advance Auto Parts
AAP
+$4.15M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$3.96M
4
DLTR icon
Dollar Tree
DLTR
+$3.82M
5
MSFT icon
Microsoft
MSFT
+$3.74M

Top Sells

Rank Stock Value
1
BAC icon
Bank of America
BAC
+$2.82M
2
KO icon
Coca-Cola
KO
+$2.82M
3
GD icon
General Dynamics
GD
+$2.82M
4
ORCL icon
Oracle
ORCL
+$2.81M
5
HLNE icon
Hamilton Lane
HLNE
+$2.8M

Sector Composition

Rank Sector Weight
1 Technology 16.51%
2 Industrials 15.72%
3 Consumer Discretionary 15.68%
4 Healthcare 13.43%
5 Financials 10.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MYGN icon
701
Myriad Genetics
MYGN
$502M
$313K 0.04%
+11,443
New +$310K
ALV icon
702
Autoliv
ALV
$9.09B
$313K 0.04%
3,353
-7,130
-68% -$710K
ATNI icon
703
ATN International
ATNI
$370M
$313K 0.04%
9,668
-443
-4% -$11.7K
TBLA icon
704
Taboola.com
TBLA
$1.37B
$310K 0.04%
92,287
-47,557
-34% -$157K
BIO icon
705
Bio-Rad Laboratories Class A
BIO
$8.86B
$310K 0.04%
+926
New +$294K
SIRI icon
706
SiriusXM
SIRI
$10.7B
$310K 0.04%
+13,095
New +$407K
LMAT icon
707
LeMaitre Vascular
LMAT
$2.34B
$303K 0.04%
3,263
-660
-17% -$57.2K
LIND icon
708
Lindblad Expeditions
LIND
$1.95B
$303K 0.04%
32,744
+752
+2% +$6.99K
HXL icon
709
Hexcel
HXL
$8.3B
$302K 0.04%
4,889
-23,465
-83% -$1.48M
PAY icon
710
Paymentus
PAY
$4.29B
$301K 0.04%
15,053
-1,933
-11% -$40.5K
EB
711
DELISTED
Eventbrite
EB
$301K 0.04%
+110,171
New +$419K
NMIH icon
712
NMI Holdings
NMIH
$3.34B
$301K 0.04%
7,300
-413
-5% -$15.9K
WTW icon
713
Willis Towers Watson
WTW
$29.9B
$300K 0.04%
1,019
-8,473
-89% -$2.37M
ACCO icon
714
Acco Brands
ACCO
$401M
$300K 0.04%
54,840
-43,137
-44% -$218K
FPI
715
Farmland Partners
FPI
$417M
$299K 0.04%
28,652
-5,855
-17% -$61.9K
CWCO icon
716
Consolidated Water Co
CWCO
$484M
$298K 0.04%
11,839
-12
-0.1% -$320
HTO
717
H2O America
HTO
$2.69B
$298K 0.04%
5,123
-6,341
-55% -$371K
LYB icon
718
LyondellBasell Industries
LYB
$18.8B
$297K 0.04%
+3,096
New +$297K
SHEN icon
719
Shenandoah Telecom
SHEN
$655M
$295K 0.04%
+20,929
New +$346K
TXG icon
720
10x Genomics
TXG
$5.97B
$295K 0.04%
+13,058
New +$270K
ALTG icon
721
Alta Equipment Group
ALTG
$207M
$294K 0.04%
43,599
-9,148
-17% -$70.3K
WDAY icon
722
Workday
WDAY
$39.4B
$293K 0.04%
1,199
-7,814
-87% -$1.85M
AFYA icon
723
Afya
AFYA
$1.32B
$292K 0.04%
+17,134
New +$297K
OIS icon
724
Oil States International
OIS
$483M
$292K 0.03%
63,488
-65,784
-51% -$315K
FULC icon
725
Fulcrum Therapeutics
FULC
$248M
$292K 0.03%
+81,735
New +$606K
27 28
29
30 31

Similar funds

SAF
Smith Anglin Financial Dallas, Texas $1.1B AUM 14.08% 1-Year Est. Return
GIM
Grassi Investment Management Santa Clara, California $1.26B AUM 23.4% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
PP
PrairieView Partners St. Paul, Minnesota $1.03B AUM 11.4% 1-Year Est. Return
FC
Forte Capital Rochester, New York $930M AUM 24.11% 1-Year Est. Return
HIP
HPS Investment Partners New York $1.52B AUM 19.81% 1-Year Est. Return
SC
Savoie Capital Chicago, Illinois $805M AUM 19.48% 1-Year Est. Return
BWA
Bordeaux Wealth Advisors Menlo Park, California $781M AUM 26.55% 1-Year Est. Return

Nebula Research & Development's Q3 2024 Portfolio in Review

As of Q3 2024, Nebula Research & Development held 1,220 positions worth $836M, up 35% from $618M the previous quarter. Its ten largest holdings account for 4.5% of the portfolio.

Nebula Research & Development deployed $188M of net new capital in Q3 2024, opening 441 new positions and adding to 247 existing holdings. Its largest new stake was BioMarin Pharmaceuticals: 52,699 shares worth $3.7M.

By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 16% a quarter earlier, followed by Industrials and Consumer Discretionary.

On the sell side, the largest reduction was Travelers Companies, an estimated $2.39M trimmed.

  • Nebula Research & Development's largest Q3 2024 buy was BioMarin Pharmaceuticals: 52,699 shares worth $3.7M.
  • Nebula Research & Development added most to Dollar Tree in Q3 2024, an estimated $3.82M increase.
  • Nebula Research & Development's biggest Q3 2024 reduction was Travelers Companies, cutting an estimated $2.39M.
  • Nebula Research & Development fully exited Bank of America in Q3 2024, selling an estimated $2.82M.
  • Nebula Research & Development's ten largest holdings make up 4.5% of its $836M portfolio in Q3 2024.
  • Nebula Research & Development opened 441 new positions and closed 319 in Q3 2024.
  • Nebula Research & Development's portfolio value rose 35% quarter-over-quarter to $836M.

Based on Nebula Research & Development's 13F filing for Q3 2024, filed 14 Nov 2024.